Picture of Yield10 Bioscience logo

YTENQ — Yield10 Bioscience News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Yield10 Bioscience Inc expected to post a loss of 65 cents a share - Earnings Preview

* Yield10 Bioscience Inc  YTEN.OQ   YTEN.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
14. 
    * The Woburn Massachusetts-based  company is expected to
report  a
44.6% increase in revenue to $133 thousand from $92 thousand a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Yield10 Bioscience
Inc is
for a loss of 65 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Yield10
Bioscience Inc is $9.5​, above​ its last closing price of $2.53.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.69       -0.69      -0.70     Missed  -1.4
 Mar. 31 2022  -0.65       -0.65      -0.68     Missed  -4.2
 Dec. 31 2021  -0.64       -0.63      -0.61     Beat    3.9​
 Sep. 30 2021  -0.65       -0.65      -0.49     Beat    24.6
 ​​Jun.        -0.54       -0.54      -0.64     Missed  -18.5
 30 2021                                                
 Mar. 31 2021  -0.54       -0.55      -0.60     Missed  -8.1​
 Dec. 31 2020              -0.70      -0.79     Missed  -13.3
 Sep. 30 2020  -0.95       -0.94      -0.87     Beat    7.9
 This summary was machine generated November 11 at 22:19 GMT. 
All figures in US dollars  unless otherwise stated

Recent news on Yield10 Bioscience

See all news